Leaps by Bayer has co-led a $28.5m series A round disclosed when precision medicine startup Vesigen Therapeutics publicly launched.
US-based precision medicine developer Vesigen Therapeutics has emerged from stealth with $28.5m in a series A round co-led by Leaps by Bayer, an investment vehicle for pharmaceutical and chemicals producer Bayer.
Venture capital firm Morningside Ventures co-led the round, which also attracted Alexandria Venture Investments, the VC arm of life sciences real estate investment trust Alexandria Real Estate Equities, and biotech investment firm Linden Lake Ventures.
Vesigen is developing drugs based on fusogenic extracellular vesicles, parts of a cell which…
